Kodu・Aktsiate loetelu・CytoSorbents Corp

CytoSorbents Corp

Suletud

SektorTervishoid

0.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.35

Max

0.36

Põhinäitajad
By Trading Economics
Sissetulek	-4.4M -9.5M
Müük	769K 9.6M
Aktsiakasum	-0.07
Kasumimarginaal	-99.107
Töötajad	129
EBITDA	547K -3.3M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+108.33% upside

Dividendid
By Acuity
Järgmine tulemuste avaldamine	12. nov 2026

Turustatistika
By TradingEconomics
Turukapital	-383K 23M
Eelmine avamishind	0.36
Eelmine sulgemishind	0.36

Uudiste sentiment

By Acuity

50%

135 / 340 Pingereas Healthcare

CytoSorbents Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. aug 2026, 22:01 UTC

Cytosorbents Corp shares are higher in after-market trading, following notable activity after the market closed, despite no specific company news identified.

10. aug 2026, 19:21 UTC

News

Cytosorbents Corp shares are higher, driven by gains in the Health Care Equipment sector. The company reported Q2 revenue of $9.63 million, exceeding forecasts.

7. aug 2026, 20:51 UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6. aug 2026, 19:16 UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5. aug 2026, 22:06 UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4. aug 2026, 21:01 UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3. aug 2026, 19:56 UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31. juuli 2026, 20:06 UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29. juuli 2026, 20:08 UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28. juuli 2026, 18:46 UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

27. juuli 2026, 18:41 UTC

Cytosorbents Corp shares are lower today amid notable volatility, with no specific news identified to explain the decline during Monday's session.

24. juuli 2026, 19:06 UTC

Cytosorbents Corp shares are lower, marking three consecutive daily declines amid a broader market pullback influenced by falling crude oil prices.

22. juuli 2026, 20:13 UTC

Cytosorbents Corp shares are lower in after-market hours amid rising crude oil prices and escalating U.S.-Iran tensions. The stock remains below its 20-day moving average.

21. juuli 2026, 18:31 UTC

Cytosorbents Corp shares are higher today, reflecting broader market optimism despite earlier fluctuations. Strong buying in technology stocks supports this upward movement.

20. juuli 2026, 19:16 UTC

News

Cytosorbents plans to report second-quarter 2026 results on August 6. The company is also pursuing FDA and Health Canada approval for its DrugSorb®-ATR device.

Võrdlus sarnastega

Hinnamuutus

CytoSorbents Corp Prognoos

Hinnasiht

By TipRanks

108.33% tõus

12 kuu keskmine prognoos

Keskmine 0.75 USD 108.33%

Kõrge 0.75 USD

Madal 0.75 USD

Põhineb 1 Wall Streeti analüütiku instrumendi CytoSorbents Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi CytoSorbents Corp aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

135 / 340 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.